I placebokontrollerede forsøg var frekvensen af afbrudt behandling, pga. bivirkninger, 15, 7% for patienter, der fik rimonabant.
In placebo-controlled studies, the discontinuation rate due to adverse reactions was 15.7% for patients receiving rimonabant.